CA-QUALCOMM-INCORPORATED
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on June 20, 2024, to stockholders of record at the close of business on May 30, 2024.
About Qualcomm
Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated. For more information, visit www.qualcomm.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press release
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4 Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is estimated to affect up to 111 people per 100,000 in the EU5-10 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis11-13 This positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the granting of marketing authorization of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo n
FPT and DENSO Sign MOU to Accelerate Software-Defined Vehicle Innovation13.12.2024 06:58:00 CET | Press release
Global IT corporation FPT and global automotive components manufacturer DENSO signed a Memorandum of Understanding (MOU) to collaborate on advancing software-defined vehicles (SDV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212915049/en/ The signing ceremony took place at DENSO Corporation Aichi Headquarters with the participation of Dr Truong Gia Binh, Chairman of FPT Corporation, Mr Shinnosuke Hayashi, President & CEO of DENSO Corporation, and senior leaders of both companies. (Photo: Business Wire) Under this MOU, the two companies will develop software for next-generation SDVs, with a particular emphasis on mass-production projects for Advanced Driver Assistance Systems (ADAS). Both companies aim to build a high-speed, high-quality global development framework, with plans for expansion by the end of 2027. The partnership is backed by FPT’s two decades of experience in automotive, a global team of 5,000 automotive
Kao Corporation: Regarding Shareholder Statement13.12.2024 05:48:00 CET | Press release
Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders. Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges. Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates. The timing of the announcem
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor13.12.2024 01:30:00 CET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally de
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas12.12.2024 23:30:00 CET | Press release
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable GrowthExpected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279) and Rusfertide (TAK-121)Regulatory Filings for Oveporexton (Narcolepsy Type 1), Zasocitinib (Psoriasis) and Rusfertide (Polycythemia Vera) on Track for Fiscal Years 2025 - 2026Five Additional Filings Anticipated in Fiscal Years 2027 - 2029 Including First Indication Submissions for Mezagitamab (TAK-079), Fazirsiran (TAK-999) and Elritercept (TAK-226) Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom